Unbound MEDLINE

[Osteonecrosis of the jaw secondary to oral alendronate: Report of three cases.] Revista médica de Chile [Rev Med Chil] Journal article

 
Title[Osteonecrosis of the jaw secondary to oral alendronate: Report of three cases.]
Author(s)Bocanegra-Pérez S, Vicente-Barrero M, Sosa-Henríquez M, Gebaguer Blanco A, Knezevic M, Castellano-Navarro JM 
InstitutionAtención Primaria del Servicio Canario, Hospital Universitario Insular, Las Palmas, España.
SourceRev Med Chil 2009 Feb; 137(2):275-9.
AbstractOsteonecrosis of the jaw associated to biphosphonate use is more common in cancer patients with bone metastases, that are using intravenous diphosphonates. When these drugs are used orally the risk of the complication is lower. We report 3 diabetic women aged 69, 76 and 82 years, receiving alendronate 70 mg every one week. The unveiling event was the extraction of several teeth without the use of antibiotics. All had bone pain, purulent discharge, loss of bone and halitosis. All improved five months after discontinuing alendronate.
Languagespa
Pub Type(s)English Abstract
Journal Article
PubMed ID19543652
  
Advertise on this site.